Impact News +++ Bunge Diverts Argentina Soybean Meal Ship Bound for China (Bloomberg) +++ BUNGE Aktie +3,10%

KRYSTAL BIOTECH Aktie

>KRYSTAL BIOTECH Aktienkurs

125.2 EUR (Tradegate)

Ask: 125.75 EUR / 160 Stück

Bid: 124.65 EUR / 160 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 8 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>KRYSTAL BIOTECH Performance

1 Woche: -1,3%

1 Monat: -1,4%

3 Monate: +5,7%

6 Monate: -28,8%

1 Jahr: -30,8%

laufendes Jahr: -17,7%

>KRYSTAL BIOTECH Aktie

Name:

KRYSTAL BIOTECH DL-,00001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US5011471027 / A2JH2F

Symbol/ Ticker:

4KB (Frankfurt) / KRYS (NASDAQ)

Kürzel:

FRA:4KB, ETR:4KB, 4KB:GR, NASDAQ:KRYS

Index:

Webseite:

https://www.krystalbio.co..

Profil:

Krystal Biotech Inc. is a biotechnology company pr..
>Volltext..

Marktkapitalisierung:

3626.63 Mio. EUR

Unternehmenswert:

3056.62 Mio. EUR

Umsatz:

307.65 Mio. EUR

EBITDA:

135.37 Mio. EUR

Nettogewinn:

125.67 Mio. EUR

Gewinn je Aktie:

4.36 EUR

Schulden:

8.29 Mio. EUR

Liquide Mittel:

303.05 Mio. EUR

Operativer Cashflow:

167.35 Mio. EUR

Bargeldquote:

7.85

Umsatzwachstum:

96.48%

Gewinnwachstum:

25.93%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

KRYSTAL BIOTECH

Letzte Datenerhebung:

20.08.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 28.94 Mio. St.

Frei handelbar: 85.85%

Leerverk. Aktien: 11.81%

Rückkaufquote: -0.21%

Mitarbeiter: 275

Umsatz/Mitarb.: 0.9 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 43.22%

Bewertung:

KGV: 29.81

KGV lG: 28.45

KUV: 12.08

KBV: 4.07

PEG-Ratio: 0.86

EV/EBITDA: 22.58

Rentabilität:

Bruttomarge: 91.63%

Gewinnmarge: 40.85%

Operative Marge: 42.26%

Managementeffizenz:

Gesamtkaprendite: 14.27%

Eigenkaprendite: 15.61%

>Peer Group

Es sind 601 Aktien bekannt.

>KRYSTAL BIOTECH Chart & Kurs - NASDAQ

>KRYSTAL BIOTECH News

04.08.25 - 18:48	Krystal Biotech sees global VYJUVEK expansion and expects Q3 revenue dip before renewed growth (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.08.25 - 16:00	Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates (Zacks)
	Krystal Biotech (KRYS) delivered earnings and revenue surprises of +19.44% and +6.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

04.08.25 - 13:12	Krystal Biotech GAAP EPS of $1.29 beats by $0.16, revenue of $96.04M beats by $4.08M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.07.25 - 00:06	Heres How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today (Benzinga)
	read more...

28.07.25 - 17:30	Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth (Zacks)
	Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

25.07.25 - 15:03	Krystal Biotech Announces Approval of VYJUVEK® by Japan′s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa (GlobeNewswire EN)
	VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family...

17.07.25 - 02:01	Insiderhandel: President, R&D verkauft Aktien von Krystal Biotech im Wert von 4033240 USD (Insiderkauf)
	Krishnan, Suma - Vorstand - Tag der Transaktion: 2025-07-14...

17.07.25 - 02:01	Insiderhandel: President, R&D verkauft Aktien von Krystal Biotech im Wert von 924061 USD (Insiderkauf)
	Krishnan, Suma - Vorstand - Tag der Transaktion: 2025-07-15...

17.07.25 - 02:01	Insiderhandel: President, R&D verkauft Aktien von Krystal Biotech im Wert von 437700 USD (Insiderkauf)
	Krishnan, Suma - Vorstand - Tag der Transaktion: 2025-07-16...

12.07.25 - 05:01	Insiderhandel: President, R&D verkauft Aktien von Krystal Biotech im Wert von 2062793 USD (Insiderkauf)
	Krishnan, Suma - Vorstand - Tag der Transaktion: 2025-07-10...

12.07.25 - 05:01	Insiderhandel: President, R&D verkauft Aktien von Krystal Biotech im Wert von 60042 USD (Insiderkauf)
	Krishnan, Suma - Vorstand - Tag der Transaktion: 2025-07-09...

10.07.25 - 19:45	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
	Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis....

09.07.25 - 13:03	Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis (GlobeNewswire EN)
	Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye...

04.07.25 - 18:27	Heres How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years (Benzinga)
	read more...

25.06.25 - 19:00	KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study (Zacks)
	Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage....

25.06.25 - 17:30	Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength? (Zacks)
	Krystal Biotech (KRYS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term....

24.06.25 - 13:03	Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa (GlobeNewswire EN)
	Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design...

05.06.25 - 19:00	Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report? (Zacks)
	Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

03.06.25 - 14:03

Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire EN)

PITTSBURGH, June 03, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 2:00 pm ET and host investor meetings throughout the day....

02.06.25 - 19:00	Implied Volatility Surging for Krystal Biotech Stock Options (Zacks)
	Investors need to pay close attention to KRYS stock based on the movements in the options market lately....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Nur übereilt bestimmt die Neigung sich. - Johann Wolfgang von Goethe

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram